• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Patient characteristics of long-term responders to mogamulizumab: results from the MAVORIC study.

作者信息

Kim Youn H, Khodadoust Michael, de Masson Adele, Moins-Teisserenc Hélène, Ito Takahiro, Dwyer Karen, Herr Fiona, Bagot Martine

机构信息

Stanford Cancer Center, Stanford, CA, United States.

Stanford University School of Medicine, Stanford, CA, United States.

出版信息

Eur J Cancer. 2021 Oct;156 Suppl 1:S48-S49. doi: 10.1016/S0959-8049(21)00715-2.

DOI:10.1016/S0959-8049(21)00715-2
PMID:34649658
Abstract
摘要

相似文献

1
Patient characteristics of long-term responders to mogamulizumab: results from the MAVORIC study.莫格利珠单抗长期缓解者的患者特征：MAVORIC研究结果
Eur J Cancer. 2021 Oct;156 Suppl 1:S48-S49. doi: 10.1016/S0959-8049(21)00715-2.
2
Efficacy of mogamulizumab in mycosis fungoides by patient blood involvement and time to response analysis in mycosis fungoides and Sézary syndrome: a post hoc analysis of the MAVORIC study.通过蕈样肉芽肿患者血液受累情况及蕈样肉芽肿和塞扎里综合征的缓解时间分析评估莫加莫珠单抗治疗蕈样肉芽肿的疗效：MAVORIC研究的事后分析
Eur J Cancer. 2021 Oct;156 Suppl 1:S47-S48. doi: 10.1016/S0959-8049(21)00714-0.
3
Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection.聚焦莫格利珠单抗 - Kpkc 在成人复发或难治性蕈样真菌病或塞扎里综合征中的应用：疗效、安全性和患者选择。
Drug Des Devel Ther. 2020 Sep 16;14:3747-3754. doi: 10.2147/DDDT.S185896. eCollection 2020.
4
Characterization and outcomes in patients with mogamulizumab-associated skin reactions in the MAVORIC trial.MAVORIC试验中莫加莫单抗相关皮肤反应患者的特征及结局
Eur J Cancer. 2021 Oct;156 Suppl 1:S46. doi: 10.1016/S0959-8049(21)00712-7.
5
Understanding relative survival outcomes for patients with cutaneous T-cell lymphoma (CTCL) subtypes mycosis fungoides and Sézary syndrome treated with mogamulizumab or vorinostat: combining Australian real-world evidence and MAVORIC phase 3 trial data.了解接受莫加莫拉单抗或伏立诺他治疗的蕈样肉芽肿和 Sézary 综合征这两种皮肤 T 细胞淋巴瘤（CTCL）亚型患者的相对生存结果：结合澳大利亚真实世界证据和 MAVORIC 3 期试验数据。
Eur J Cancer. 2021 Oct;156 Suppl 1:S18. doi: 10.1016/S0959-8049(21)00659-6.
6
Health-related quality of life effect of mogamulizumab by patient blood involvement.患者血液受累情况下莫加莫拉单抗对健康相关生活质量的影响。
Eur J Cancer. 2021 Oct;156 Suppl 1:S65-S66. doi: 10.1016/S0959-8049(21)00749-8.
7
Mogamulizumab in the treatment of advanced mycosis fungoides and Sézary syndrome: safety and efficacy.莫格利珠单抗治疗晚期蕈样霉菌病和赛泽里综合征：安全性和疗效。
Expert Rev Anticancer Ther. 2020 Jun;20(6):447-452. doi: 10.1080/14737140.2020.1760096. Epub 2020 Apr 28.
8
Successful Treatment of Erythrodermic Mycosis Fungoides with Mogamulizumab Followed by Etoposide Monotherapy.用莫加莫珠单抗继以依托泊苷单药治疗成功治愈红皮病型蕈样肉芽肿。
Case Rep Oncol. 2018 Jan 16;11(1):29-32. doi: 10.1159/000486278. eCollection 2018 Jan-Apr.
9
Cutaneous T-Cell Lymphoma: Optimizing Care in Patients Receiving Anti-CCR4 Monoclonal Antibody Mogamulizumab.皮肤T细胞淋巴瘤：优化接受抗CCR4单克隆抗体莫格利珠单抗治疗患者的护理
Clin J Oncol Nurs. 2019 Aug 1;23(4):E73-E80. doi: 10.1188/19.CJON.E73-E80.
10
Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome.莫格利珠单抗（一种去岩藻糖基化的抗 CC 趋化因子受体 4 抗体）降低侵袭性/难治性蕈样肉芽肿和塞扎里综合征患者的调节性 T 细胞。
Clin Cancer Res. 2015 Jan 15;21(2):274-85. doi: 10.1158/1078-0432.CCR-14-0830. Epub 2014 Nov 5.

引用本文的文献

1
Practical recommendations for therapy and monitoring of mogamulizumab patients in Germany.德国莫加莫拉单抗治疗患者的治疗与监测实用建议。
J Dtsch Dermatol Ges. 2025 Mar;23(3):341-354. doi: 10.1111/ddg.15639. Epub 2024 Dec 26.
2
Through thick and thin: confronting the aggressive cutaneous T-cell lymphomas.同甘共苦：直面侵袭性皮肤T细胞淋巴瘤
Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):62-68. doi: 10.1182/hematology.2024000529.
3
Clinical and Real-World Effectiveness of Mogamulizumab: A Narrative Review.
莫格利珠单抗的临床和真实世界疗效：一项叙述性综述。
Int J Mol Sci. 2024 Feb 12;25(4):2203. doi: 10.3390/ijms25042203.
4
Advances in the treatment of mycoses fungoides and Sézary syndrome: a narrative update in skin-directed therapies and immune-based treatments.蕈样肉芽肿和赛泽里综合征治疗进展：皮肤靶向治疗和免疫治疗的叙述性更新。
Front Immunol. 2023 Oct 5;14:1284045. doi: 10.3389/fimmu.2023.1284045. eCollection 2023.
5
CAR-T cell development for Cutaneous T cell Lymphoma: current limitations and potential treatment strategies.嵌合抗原受体 T 细胞治疗皮肤 T 细胞淋巴瘤：当前的局限性和潜在的治疗策略。
Front Immunol. 2022 Aug 18;13:968395. doi: 10.3389/fimmu.2022.968395. eCollection 2022.
6
Resistance to mogamulizumab is associated with loss of CCR4 in cutaneous T-cell lymphoma.对 mogamulizumab 的耐药性与皮肤 T 细胞淋巴瘤中 CCR4 的缺失有关。
Blood. 2022 Jun 30;139(26):3732-3736. doi: 10.1182/blood.2021014468.
7
Genomic and Single-Cell Landscape Reveals Novel Drivers and Therapeutic Vulnerabilities of Transformed Cutaneous T-cell Lymphoma.基因组和单细胞景观揭示了转化性皮肤 T 细胞淋巴瘤的新驱动因素和治疗弱点。
Cancer Discov. 2022 May 2;12(5):1294-1313. doi: 10.1158/2159-8290.CD-21-1207.